Public funds and foreign capital are making intensive moves! They continue to build positions in Hong Kong innovative drug stocks.

Recently, risk appetite for funds has declined, market volatility has increased significantly, and growth sectors such as innovative drugs have undergone major corrections. Against this backdrop, many public mutual funds and foreign institutions have moved south intensively to continue building positions in leading innovative drug stocks. Several fund managers also emphasized in their recent third-quarter reports that the coming years may be an important stage for key clinical data readouts, progress in overseas licensing, and realization of commercialization value for China's innovative drugs.